Bharat Biotech to begin clinical trial of COVID-19 intranasal vaccine next week
Krishna Ella, Chairman of Bharat Biotech had earlier said the company is focusing on the intranasal vaccine as the existing vaccines require two-dose intramuscular injections and a country like India needs 2.6 billion syringes and needles which may add up to pollution
BusinessToday.In | March 4, 2021 | Updated 09:37 IST
Vaccines are usually administered as injectable shots but with intranasal vaccines, the solution is squirted or sprayed into the nostrils
Bharat Biotech is likely to conduct clinical trials for an intranasal Covid-19 vaccine candidate, called BBV154, next week. The COVID-19 vaccine-making firm will conduct trials in Patna, Chennai, Hyderabad, and Nagpur. According to the Central Trail Registry of India (CTRI), these trials will be conducted on 175 participants.
Bharat Biotech to begin clinical trial of COVID-19 intranasal vaccine next week businesstoday.in - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from businesstoday.in Daily Mail and Mail on Sunday newspapers.
Bharat Biotech s nasal Covid-19 vaccine trials likely to begin next week: Sources
Bharat Biotech s nasal Covid-19 vaccine trials likely to begin next week: Sources
The process of recruiting participants for these trails is underway. The trails will be held in Patna, Chennai, Hyderabad and Nagpur.
advertisement
(Representational image. Photo: AFP)
These trails will be conducted in Patna, Chennai, Nagpur and Hyderabad.
As per the Central Trail Registry of India (CTRI), these trials will be conducted on 175 participants.
Sources have told India Today TV that the process of recruiting participants for these trails is underway and the ethics committees of these trial sites are yet to grant approval.